Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBD1119 in stable coronary artery disease
2026-525901-10-00Phase 2Authorised
- Sponsor
- Ribocure Pharmaceuticals AB
- Start
- Oct 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in coronary arteriosclerosis comparing RBD1119 with Placebo (2 arms). Primary endpoint: Percentage change from baseline in coagulation factor XI activity at Week 8. Planned start Oct 2026; status: authorised.
02
Drugs
RBD1119
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2026-525901-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525901-10-00.